Dr. Reddy's Laboratories, Incorporated

Asana Biosciences, LLC

Endo Pharmaceuticals Inc.

Asan Biosciences, LLC

Libertas Bio, Inc.

Vijay Potluri

Roger Astbury Smith

Sunil Kumar Panigrahi

Aranapakam Mudumbai Venkatesan

Scott Kevin Thompson

Subramanya Hosahalli

Pradip Kumar Sasmal

Saumitra Sengupta

Sanjeeva P Reddy

Tyler M John

Vijay Kumar Nyavanandi

Prabhakara Rao Nadipalli

Vishnu Basetti

Karunasree Kunta

Ashok Tehim

Hosahalli Subramanya

Yonghua Gai

Hang Zhang

Chintakunta Vamseekrishna

Ranjan Chakrabarti

Ish Khanna

Javed Iqbal

Saibal Kumar Das

Parimal Misra

Thomas Hogberg

Vamsee Krishna Chintakunta

Subramanya Hoshalli

Mahaboobi Jaleel

Oystein Rist

Lisbeth Elster

Thomas Michael Frimurer

Lars-Ole Gerlach

Rashmi Talwar

The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R, and Rto Rare defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer. 

Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways

The present application provides novel pyrimido-pyridazinone compounds and methods for preparing and using these compounds. These compounds are useful in treating inflammation in patients by administering one or more of the compounds to a patient. In one embodiment, the novel pyrimido-pyridazinone compound is of Formula (I) and Rand Rare defined herein. 

Pyrimido-pyridazinone compounds and methods of use thereof

The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts. wherein R, R, R, R, R, and Rare as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (&#x3ba;) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.

Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists

The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R, and Rto Rare defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment/the disease is cancer. 

The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts, wherein R, R, R, R, R, and Rare as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (&#x3ba;) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS. 

The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts. (I) Wherein A, m, R1s, R2, R3, R4 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (&#x3ba;) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS. 

Kappa opioid receptor agonists

The present application provides novel thiazole derivatives that are useful as activators of Adenosine 5'-Monophosphate-Activated Protein Kinase and pharmaceutical compositions containing such compounds.

Thiazoles derivatives as AMPK activator

Growing community of inventors

Hyderabad Telangana, India

Vijay Potluri